Search | Clinical Trials Finder

Conditions: Kidney Injury, Acute
Interventions: Sodium Nitrate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hyperkalemia
Interventions: Zirconium silicate (acute phase), Zirconium silicate (subacute phase), Placebo (acute phase), Placebo ( subacute phase); Drug
Lead sponsor: ZS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 42
States / cities: Anniston, Alabama • Huntsville, Alabama • Glendale, Arizona + 37 more

Conditions: Sexual Satisfaction, Sexual Function
Interventions: Spark Placebo Control 5.1, Spark Active Study Product 5.1 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Lennox Gastaut Syndrome
Interventions: Clemizole HCl, Placebo; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat; Other · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Interventions: AER-271, Placebo; Drug
Lead sponsor: Aeromics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: BMS-985521, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Periodontitis, Periodontal Diseases, Periodontal Pocket
Interventions: Amoxicillin, Metronidazole, Placebo; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 35 Years and older
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases, Musculoskeletal Diseases
Interventions: TNX-102 SL Tablet, 2.8 mg, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 28 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 55
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 51 more

Conditions: Healthy Volunteers
Interventions: BMS-986166, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Posttraumatic Headache, Posttraumatic Stress Disorder
Interventions: Group A active comparator, Group B active comparator, Group C Experimental, Group D Placebo Comparator; Procedure · Drug · Combination Product + 1 more
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Chicago, Illinois • Bethesda, Maryland • Fort Bragg, North Carolina

Conditions: Abuse Potential
Interventions: gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg, diazepam 20 mg, placebo; Drug · Other
Lead sponsor: Viatris Specialty LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Actinic Keratosis
Interventions: Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Tucson, Arizona • Encino, California • Los Angeles, California + 20 more

Conditions: Vasectomy, NSAIDs, Post-operative Care
Interventions: Acetaminophen, ibuprofen, oxycodone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 2
States / cities: New York, New York • White Plains, New York

Conditions: Pulmonary Arterial Hypertension (PAH)
Interventions: Allogeneic Human Cardiosphere-Derived Stem Cells, Placebo; Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Arterial Hypertension
Interventions: MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Actinic Keratosis
Interventions: Photodynamic therapy with methyl aminolevulinate cream; Procedure
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 7
States / cities: St. Petersburg, Florida • New York, New York • Rochester, New York + 4 more

Conditions: HIV
Interventions: N-803, Saline placebo; Drug
Lead sponsor: Michael Peluso, MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer's Disease
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 41
States / cities: Gilbert, Arizona • Bellflower, California • Costa Mesa, California + 31 more

Conditions: Cushing's Disease
Interventions: osilodrostat, osilodrostat Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Ann Arbor, Michigan • New York, New York + 2 more

Conditions: Diabetes
Interventions: Placebo, TAK-875; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 82
States / cities: Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 78 more

Conditions: Overactive Bladder (OAB)
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 103
States / cities: Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions: AZ compound, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 75 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

Radicle Spark for Women™ 24: Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

Phase 1 Study to Assess AER-271

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants

Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD

Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

Post-Vasectomy Pain Study

ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

Interleukin-15 to Promote Post-ART Control of HIV

Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)